-
1.发明公开
公开(公告)号：EP4269439A3
公开(公告)日：2024-01-17
申请号：EP23184844.1
申请日：2017-09-08
IPC分类号： A61K39/395 , A61P25/28 , A61P27/00 , C07K16/28
摘要： The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
2.发明公开
公开(公告)号：EP3509636A1
公开(公告)日：2019-07-17
申请号：EP17848290.7
申请日：2017-09-08
IPC分类号： A61K39/395 , A61P25/28 , A61P27/00 , C07K16/28
-
3.发明公开T-HELPER 1 ADJUVANT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS 审中-公开T-HELPER 1辅助剂治疗AMYOTRTRHIC横向性SCLEROSIS
公开(公告)号：EP3320914A1
公开(公告)日：2018-05-16
申请号：EP17209271.0
申请日：2013-09-10
发明人： EISENBACH-SCHWARTZ, Michal , FRIEDMAN, Nir , BARUCH, Kuti , KUNIS, Gilad , CAHALON, Liora , ROSENZWEIG, Neta , DECZKOWSKA, Aleksandra
IPC分类号： A61K38/21 , A61K39/00 , A61K45/06 , C12N5/00 , A61P25/00 , A61P25/28 , A61K35/17 , C12N5/0783 , C12N15/117
CPC分类号： A61K39/0007 , A61K35/17 , A61K38/217 , A61K45/06 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , A61P25/28 , C07K16/2878 , C07K2317/76 , C12N5/0636 , C12N15/117 , C12N2310/17 , C12N2320/30 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2317 , C12N2501/24 , C12N2501/25 , A61K2300/00
摘要： A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.
摘要翻译： 一种治疗有需要的受试者的中枢神经系统（CNS）的疾病，病症，病症或损伤的方法，其包括向所述受试者施用治疗有效量的活性成分，例如非脑炎或弱致脑炎 Th1佐剂和CNS特异性抗原的组合，引起所述受试者脉络丛的激活，并通过减少免疫抑制并在脉络丛中建立Th1型免疫应答来维持所述活化，从而使得抗炎免疫细胞或免疫细胞 其在脑脊液获得愈合表型以穿过脉络丛，并且积聚在由所述疾病，病症，病症或损伤引起的CNS损伤部位处。
-
4.发明公开DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR MODULATION OF SUPPRESSIVE ACTIVITY OF CD4+CD25+ REGULATORY T CELLS 审中-公开多巴胺和激动剂和拮抗剂THEREOF调制抑制CD4 + CD25 +调节T细胞的影响的
公开(公告)号：EP1626703A2
公开(公告)日：2006-02-22
申请号：EP04734482.5
申请日：2004-05-23
IPC分类号： A61K9/00
CPC分类号： A61K31/137 , A61K31/00 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Compositions and methods for modulation of the suppressive activity of CD4+CD25+ regulatory T cells (Treg) on CD4+CD25- effector T cells (Teff) are provided. An agent selected from: (i) dopamine; (ii) a dopamine precursor; (iii) a D1-R agonist; (iv) a D2-R antagonist; (v) a combination of (i) and (ii); or (vi) a combination of (i), (ii) or (iii) with (iv), down-regulates the suppressive activity of Treg and is useful for treatment of cancer. An agent selected from (i) a dopamine D2-R agonist, (ii) a dopamine D1-R antagonist , and (iii) a combination of (i) and (ii), up-regulates the suppressive activity of Treg and is useful for treatment of an autoimmune disease or for controlling graft rejection in tissue/organ transplantation.
-
公开(公告)号：EP1583506A2
公开(公告)日：2005-10-12
申请号：EP04700289.4
申请日：2004-01-06
IPC分类号： A61K6/00
CPC分类号： A61K31/7088 , A61K9/0048 , A61K38/02 , A61K38/193 , A61K38/2013 , A61K38/208 , A61K38/217 , A61K39/0008 , A61K2300/00
摘要： The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.
-
公开(公告)号：EP1456355A2
公开(公告)日：2004-09-15
申请号：EP02788490.7
申请日：2002-11-21
CPC分类号： C12N5/0645 , A61K2035/124 , C12N2502/1323
摘要： A process for the manufacture of human mononuclear phagocytic leukocytes comprises incubating monocytes isolated from a blood sample of an individual and skin segments from the same individual, removing the dermis segments from the incubation mixture and sedimenting the obtained activated mononuclear phagocytic leukocytes by centrifugation, washing and resuspending the activated phagocytic leukocytes in the medium, and evaluating the culture for its suitability for human administration. Cellular therapy products are made from the obtained cultures and are useful for promoting axonal regeneration in the CNS, wound healing and treatment of myocardial infarction.
-
7.发明公开THE USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND T CELLS TREATED THEREWITH FOR NEUROPROTECTIVE THERAPY 有权共聚物1的使用和相关肽和多肽这样处理过的T细胞疗法的神经保护
公开(公告)号：EP1248643A2
公开(公告)日：2002-10-16
申请号：EP01906631.5
申请日：2001-01-22
发明人： EISENBACH-SCHWARTZ, Michal , COHEN, Irun, R. , SELA, MichaelWeizmann Institute of Science , YOLES, Eti , KIPNIS, Jonathan
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K38/16 , A61K39/0008 , A61K2039/5158
摘要： Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
-
公开(公告)号：EP1007064A1
公开(公告)日：2000-06-14
申请号：EP97901735.7
申请日：1997-01-24
CPC分类号： C12N5/0622 , A61K35/12 , C12N2501/23 , C12N2501/25
摘要： A central nervous system (CNS) injury is treated by transplanting into the site of the CNS injury a therapeutically effective amount of astrocytes which were pre-treated by exposing them in vitro to inflammation-associated cytokines.
摘要翻译： 通过将中枢神经系统（CNS）损伤移植到CNS损伤部位来治疗治疗有效量的星形胶质细胞，其通过将它们体外暴露于炎症相关细胞因子而进行预处理。
-
9.发明公开
公开(公告)号：EP4269439A2
公开(公告)日：2023-11-01
申请号：EP23184844.1
申请日：2017-09-08
IPC分类号： C07K16/28
摘要： The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
10.发明公开
公开(公告)号：EP3725370A1
公开(公告)日：2020-10-21
申请号：EP19170438.6
申请日：2019-04-19
发明人： YOLES, Ester , DAVID, Carol , BARUCH, Kuti , EISENBACH-SCHWARTZ, Michal , OLSEN KROGH, Berit , JENSEN, Allan , EGEBJERG, Jan
摘要： The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.026 秒)
